Elasomeran
Highest phase reached
Approved
Drug type
Oligonucleotide
First approval year
2021
- First approval year
- 2021
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Oligonucleotide
- Drug name
- Elasomeran
- Spikevax (previously covid-19 vaccine moderna)
- spikevax previously covid 19 vaccine moderna
- biological mrna 1273
- Biological: mRNA-1273
- cx 024414
- Cx-024414
- CX-024414
- elasomeran
- Elasomeran
- elasomeran [INN]
- ELASOMERAN [JAN]
- Elasomeran [WHO-DD]
- elasomeran inn
- elasomeran jan
- elasomeran who dd
- m 1273
- M-1273
- MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING A FULL-LENGTH, CODONOPTIMISED PRE-FUSION STABILISED CONFORMATION VARIANT (K986P AND V987P) OF THE SARS-COV-2 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; GENBANK ID MN908947.3) SPIKE (S) GLYCOPROTEIN, FURTHER OPTIMIZED BY TWO ADDITIONAL STOP CODONS, FLANKED BY AN ARTIFICIAL 5' UNTRANSLATED REGION (UTR) AND A 3' UTR DERIVED FROM THE HUMAN ALPHA GLOBIN GENE (HBA1) AND TERMINATED BY A 3' POLY(A) TAIL; CONTAINS N1-METHYLPSEUDOURIDINE INSTEAD OF URIDINE (ALL-U>M1.PSI.)
- messenger rna mrna 5 capped encoding a full length codonoptimised pre fusion stabilised conformation variant k986p and v987p of the sars cov 2 severe acute respiratory syndrome coronavirus 2 genbank id mn908947 3 spike s glycoprotein further optimized by two additional stop codons flanked by an artificial 5 untranslated region utr and a 3 utr derived from the human alpha globin gene hba1 and terminated by a 3 poly a tail contains n1 methylpseudouridine instead of uridine all u m1 psi
- moderna covid 19 vaccine rna
- Moderna covid-19 vaccine rna
- mrna 1273
- mrna based vaccine encoding a pre fusion stabilized spike protein from the 2019 novel coronavirus 2019 ncov
- mRNA-1273
- Mrna-1273
- MRNA-1273
- mRNA-1273 (Moderna COVID-19 vaccine)
And 11 more, listed on the interactive page.
- CAS registry numbers
- 2430046-03-8
- ChEMBL ID
- CHEMBL4650491
- RxNorm IDs (RxCUI)
- 2470232
- FDA ingredient codes (UNII)
- EPK39PL4R4
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -meran
Mechanisms of action
- Mechanism
- Spike glycoprotein vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Spike glycoprotein
- Protein identifier
- P0DTC2
Open Targets mechanisms
- Mechanism
- Spike glycoprotein vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Spike glycoprotein
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Pneumococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000772
- Subject identifier
- D011008
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Herpes Zoster
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006510
- Subject identifier
- D006562
- Condition
- Respiratory Syncytial Virus Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001413
- Subject identifier
- D018357
- Condition
- COVID-19
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000772
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006510
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001413
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005100
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005109
- Condition identifier
- MONDO_0005265
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006594
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008054
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011429
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0016264
- Condition identifier
- MONDO_0100096
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 4
- Event
- chest pain
- Reports
- 9
- Reporting signal score
- 12.7844
- Event
- chills
- Reports
- 5
- Reporting signal score
- 6.47429
- Event
- chronic respiratory disease
- Reports
- 1
- Reporting signal score
- 5.91932
- Event
- covid-19
- Reports
- 9
- Reporting signal score
- 22.9454
- Event
- eosinopenia
- Reports
- 1
- Reporting signal score
- 6.15092
- Event
- fibrin d dimer increased
- Reports
- 3
- Reporting signal score
- 11.8129
- Event
- hepatosplenomegaly
- Reports
- 2
- Reporting signal score
- 7.49043
- Event
- herpes zoster reactivation
- Reports
- 1
- Reporting signal score
- 6.02842
- Event
- humoral immune defect
- Reports
- 4
- Reporting signal score
- 27.4017
- Event
- hypersensitivity myocarditis
- Reports
- 3
- Reporting signal score
- 21.9153
- Event
- icterus index increased
- Reports
- 1
- Reporting signal score
- 8.18712
- Event
- immunisation reaction
- Reports
- 1
- Reporting signal score
- 6.39587
- Event
- infectious mononucleosis
- Reports
- 2
- Reporting signal score
- 8.04234
- Event
- interchange of vaccine products
- Reports
- 1
- Reporting signal score
- 8.03299
- Event
- linear iga disease
- Reports
- 2
- Reporting signal score
- 7.76137
- Event
- livedo reticularis
- Reports
- 2
- Reporting signal score
- 7.76137
- Event
- myocarditis
- Reports
- 5
- Reporting signal score
- 16.9312
- Event
- occipital lobe stroke
- Reports
- 1
- Reporting signal score
- 8.36942
- Event
- pemphigoid
- Reports
- 7
- Reporting signal score
- 27.0876
- Event
- peripheral embolism
- Reports
- 2
- Reporting signal score
- 8.87191
- Event
- splinter
- Reports
- 1
- Reporting signal score
- 5.97238
- Event
- throat irritation
- Reports
- 3
- Reporting signal score
- 6.01238
- Event
- toxic epidermal necrolysis
- Reports
- 4
- Reporting signal score
- 11.3304
- Event
- transplant rejection
- Reports
- 2
- Reporting signal score
- 7.21402
- Event
- vaccination failure
- Reports
- 2
- Reporting signal score
- 10.3652
- NCT04283461
- NCT04405076
- NCT04470427
- NCT04677660
- NCT04748471
- NCT04785144
- NCT04796896
- NCT04813796
- NCT04885907
- NCT04889209
- NCT04894435
- NCT04927065
- NCT04930770
- NCT04952402
- NCT04969250
- NCT05137236
- NCT05197153
- NCT05228730
- NCT05249829
- NCT05280158
- NCT05289037
- NCT05324319
- NCT05345873
- NCT05543356
- NCT05584202
And 9 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (92)
- A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
- A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
- A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
- A Study of Modified mRNA Vaccines in Healthy Adults
- A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
- A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
- A Study of TAK-919 in Healthy Japanese Adults (COVID-19)
- A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
- A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
- A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
- A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
- A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
- A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
- A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
- A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
- A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
- A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
- A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
Approved for (2)
In development for (3)
- Herpes zoster Phase 3
- Pneumococcal infection Phase 3
- Respiratory syncytial virus infectious disease Phase 3